BioMarin Pharmaceutical Inc

BioMarin insider sale: EVP Hubbard Cristin sells 2,318 shares at $50.20—examining the move’s impact on stock, investor sentiment, and future biotech prospects.

BioMarin CEO Hardy Alexander sells 4,252 shares amid a down‑trend; investors learn this routine insider sale signals personal wealth management, not distress.

BioMarin insider buys signal confidence: EVP Friberg’s $55.46 trade and RSU/option grants suggest leadership sees upside amid a 22% yearly dip.

BioMarin insider trading shows CTO’s modest sell‑offs reflect risk‑hedging, not a bearish outlook—yet the company’s robust enzyme pipeline may buoy investor confidence.

BioMarin insider buys signal strong confidence in its enzyme pipeline and VOXZOGO, hinting at rising stock value and strategic growth.

BioMarin insider buying signals confidence—CFO and EVP purchases show optimism amid Amicus acquisition and solid capital structure.